NetScientific: refinanced and focused on enhancing value

NetScientific PLC is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities.

() noted that the temporary suspension by portfolio company () of patient recruitment for one of their clinical studies is not expected to affect the overall timing of clinical data.

PDS issued a statement announcing that the Phase 2 clinical trial led by the National Cancer Institute (NCI), evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV cancers, had paused recruitment due to an issue that is not specific to the trial itself.

The issue is unrelated to any safety or efficacy concerns with the triple combination, NetScientific said, and it is anticipated that it will be determined in a timely manner with trial recruitment to then resume immediately.

PDS chief medical officer Dr Lauren Wood said: “We know from the interim data that this combination has the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV16-associated cancers who have limited treatment options.

NetScientific PLC (AIM:NSCI, FRA:NTK1) said investee company PDS Biotechnology Corporation (NASDAQ:PDSB) has completed enrolment of the first stage of its phase II head and neck cancer clinical trial.

The checkpoint inhibitor naive arm of its VERSATILE-002 study will treat people with recurrent and/or metastatic human papillomavirus (HPV16) form of the disease.

A City broker has raised its valuation for shares in NetScientific PLC (AIM:NSCI, FRA:NTK1), saying the potential of its investment portfolio still isn’t being fully understood or recognised by the market.

It was a topic touched upon in Wednesday’s interim figures: “The board remains of the view that the market significantly undervalues the group, with current price below fair value, but without taking into account growth opportunities.”